Navigation Links
Ambit Announces Participation At 12th Annual BIO Investor Forum
Date:10/2/2013

SAN DIEGO, Oct. 2, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the 12th Annual BIO Investor Forum to be held at the Palace Hotel in San Francisco, October 8-9, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, Quizartinib, at 2:30 p.m. PT/ 5:30 p.m. ET on Wednesday, October 9.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

The 12th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. The BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

 Ambit Contacts: Marcy Graham

Ian Stone/David SchullExecutive Director, Investor Relations & Corp Comm

Media ContactsAmbit Biosciences, Inc.

Russo Partners858-334-2125

619-308-6541/212-845-4271mgraham@ambitbio.com  

ian.stone@russopartnersllc.com/david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
2. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
3. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
4. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
5. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
6. Ambit Biosciences to Present at Two Upcoming Investor Conferences
7. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
8. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
9. Sigma-Aldrich Announces Q3 2013 Earnings Conference Call
10. MUSA Announces Partnership with IPERION
11. Global Stem Cells Group, Inc. Announces Worldwide Alliance with EmCyte Corp. to Promote In-office Regenerative Medicine Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):